methylprednisolone sodium succinate

P1/2, N=10, Terminated, Masonic Cancer Center, University of Minnesota | N=55 --> 10 | Trial completion date: Sep 2028 --> Feb 2026 | Suspended --> Terminated | Trial primary completion date: Sep 2026 --> Feb 2026; Sponsor terminated financial support

P=N/A, N=81, Completed, Xijing Hospital of Digestive Diseases

P4, N=200, Recruiting, Chinese PLA General Hospital | Not yet recruiting --> Recruiting | Trial completion date: Jun 2026 --> Jun 2029 | Trial primary completion date: Jun 2026 --> Jun 2027

P1/2, N=15, Recruiting, Prevail Therapeutics | Active, not recruiting --> Recruiting

P2, N=30, Not yet recruiting, Brigham and Women's Hospital

P2, N=40, Recruiting, Hoffmann-La Roche | Trial completion date: Sep 2029 --> Jun 2030 | Trial primary completion date: Aug 2027 --> Jun 2028

P2, N=60, Recruiting, Mayo Clinic | Trial completion date: Jul 2026 --> Jul 2027 | Trial primary completion date: Feb 2026 --> Feb 2027

P1/2, N=55, Suspended, Masonic Cancer Center, University of Minnesota | Recruiting --> Suspended

P1, N=35, Not yet recruiting, Baylor College of Medicine | Initiation date: Jan 2026 --> Jun 2026

We report a fulminant case of overlap syndrome involving ICI-induced myositis and myasthenia gravis in a 72-year-old man receiving ipilimumab-nivolumab for hepatocellular carcinoma and recurrent renal cell carcinoma...Despite prompt intensive care admission and treatment with high-dose intravenous methylprednisolone and intravenous immunoglobulin, only partial clinical improvement was achieved. The subsequent development of aspiration pneumonia led to acute respiratory and hepatic failure, culminating in death. This case underscores the aggressive clinical trajectory and high mortality of ICI-related neuromuscular overlap syndromes, highlighting the critical need for early recognition, rapid immunosuppression, and multidisciplinary management.

P3, N=110, Recruiting, Fondation Hôpital Saint-Joseph | Trial primary completion date: Oct 2025 --> Mar 2026

P2, N=163, Recruiting, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Trial completion date: May 2027 --> Feb 2027 | Trial primary completion date: Apr 2027 --> Aug 2026